サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1536124

神経疾患治療学の世界市場

Neurologic Disorders Therapeutics

出版日
ページ情報
英文 289 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
神経疾患治療学の世界市場
出版日: 2024年08月16日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 289 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

神経疾患治療学の世界市場は2030年までに1,497億米ドルに達する見込み

2023年に1,164億米ドルと推定される神経疾患治療学の世界市場は、2030年には1,497億米ドルに達し、分析期間2023-2030年のCAGRは3.7%で成長すると予測されます。本レポートで分析したセグメントの1つである抗コリン薬クラスは、CAGR 4.0%を記録し、分析期間終了時には452億米ドルに達すると予測されます。鎮痛薬クラス別セグメントの成長率は、分析期間中CAGR 4.4%と推定されます。

米国市場は317億米ドルと推定、中国はCAGR 7.0％で成長予測

米国の神経疾患治療学市場は2023年に317億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに313億米ドルの市場規模に達すると予測され、分析期間2023-2030年のCAGRは7.0%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.2%と2.8%と予測されています。欧州では、ドイツがCAGR 2.0%で成長すると予測されています。

世界の神経疾患治療学市場- 主な促進要因と動向のまとめ

神経疾患には、脳、脊髄、末梢神経を含む神経系に影響を及ぼす幅広い疾患が含まれます。これらの疾患は衰弱させる可能性があり、アルツハイマー病、パーキンソン病、多発性硬化症、てんかん、脳卒中などの疾患が含まれます。神経疾患に対する治療アプローチは特定の疾患によって大きく異なるが、一般的には症状を管理し、疾患の進行を遅らせ、患者の生活の質を改善することを目的としています。治療には、薬物療法、理学療法、作業療法、生活習慣の改善、場合によっては外科的介入が含まれます。

神経疾患の治療分野は、過去数十年の間に大きな進歩を遂げてきました。疾患修飾療法の開発は、多発性硬化症やパーキンソン病のような疾患の管理を一変させ、対症療法にとどまらない選択肢を患者に提供しました。例えば、モノクローナル抗体やその他の生物学的製剤のイントロダクションは、これらの疾患の根本的な病態生理学を標的とする新たな道を提供しました。また、神経画像やバイオマーカー研究の進歩により、早期診断や個別化された治療計画が強化されています。さらに、髄腔内ポンプや経皮パッチなどの革新的なドラッグデリバリーシステムにより、神経学的薬剤投与の有効性と利便性が向上しています。

神経疾患治療学市場の成長は、いくつかの要因によって牽引されています。第一に、特に高齢化社会における神経疾患の有病率の増加により、効果的な治療に対する需要が高まっています。第二に、バイオテクノロジーや製薬研究の進歩により、遺伝子治療や神経保護剤など、新しく改良された治療法が次々と開発されています。新興市場におけるヘルスケア・インフラの拡充も、神経学的治療へのアクセスを向上させ、市場成長に寄与しています。さらに、製薬会社、学術機関、研究機関の戦略的提携により、革新的な治療法の発見と商業化が加速しています。遠隔医療やウェアラブル端末を含むデジタルヘルス技術の台頭は、患者のモニタリングと管理を強化し、転帰の改善につながっています。最後に、神経学研究への資金提供の増加と包括的な治療ガイドラインの開発により、神経疾患の管理に対するより体系的で効果的なアプローチが促進されています。

調査対象企業の例（全86件）

  • AstraZeneca PLC
  • Biogen, Inc.
  • Biohaven, Ltd.
  • Eisai Co., Ltd.
  • H. Lundbeck A/S
  • Ionis Pharmaceuticals, Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Neurelis, Inc.
  • Neurocrine Biosciences, Inc.
  • Neurona Therapeutics, Inc.
  • Ovid Therapeutics, Inc.
  • Pfizer, Inc.
  • Sanofi SA
  • UCB SA
  • Voyager Therapeutics, Inc.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP26617

Global Neurologic Disorders Therapeutics Market to Reach US$149.7 Billion by 2030

The global market for Neurologic Disorders Therapeutics estimated at US$116.4 Billion in the year 2023, is expected to reach US$149.7 Billion by 2030, growing at a CAGR of 3.7% over the analysis period 2023-2030. Anticholinergic Drug Class, one of the segments analyzed in the report, is expected to record a 4.0% CAGR and reach US$45.2 Billion by the end of the analysis period. Growth in the Analgesics Drug Class segment is estimated at 4.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$31.7 Billion While China is Forecast to Grow at 7.0% CAGR

The Neurologic Disorders Therapeutics market in the U.S. is estimated at US$31.7 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$31.3 Billion by the year 2030 trailing a CAGR of 7.0% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.2% and 2.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.0% CAGR.

Global Neurologic Disorders Therapeutics Market - Key Drivers and Trends Summarized

Neurologic disorders encompass a broad range of conditions that affect the nervous system, including the brain, spinal cord, and peripheral nerves. These disorders can be debilitating and include diseases such as Alzheimer's, Parkinson's, multiple sclerosis, epilepsy, and stroke, among others. The therapeutic approaches for neurologic disorders vary widely depending on the specific condition, but generally aim to manage symptoms, slow disease progression, and improve the quality of life for patients. Treatments can include medications, physical and occupational therapy, lifestyle changes, and, in some cases, surgical interventions.

The field of neurologic disorder therapeutics has seen significant advancements over the past few decades. The development of disease-modifying therapies has transformed the management of conditions like multiple sclerosis and Parkinson's disease, offering patients options that go beyond symptomatic relief. For instance, the introduction of monoclonal antibodies and other biologic drugs has provided new avenues for targeting the underlying pathophysiology of these diseases. Advances in neuroimaging and biomarker research have also enhanced early diagnosis and personalized treatment plans. Moreover, innovative drug delivery systems, such as intrathecal pumps and transdermal patches, have improved the efficacy and convenience of administering neurologic medications.

The growth in the neurologic disorders therapeutics market is driven by several factors. Firstly, the increasing prevalence of neurologic conditions, particularly among aging populations, has heightened the demand for effective treatments. Secondly, advancements in biotechnology and pharmaceutical research are continuously leading to the development of new and improved therapies, including gene therapies and neuroprotective agents. The expansion of healthcare infrastructure in emerging markets has also facilitated better access to neurologic care, contributing to market growth. Additionally, strategic collaborations between pharmaceutical companies, academic institutions, and research organizations are accelerating the discovery and commercialization of innovative treatments. The rise of digital health technologies, including telemedicine and wearable devices, is enhancing patient monitoring and management, leading to better outcomes. Lastly, increased funding for neurologic research and the development of comprehensive treatment guidelines are fostering a more structured and effective approach to managing neurologic disorders.

Select Competitors (Total 86 Featured) -

  • AstraZeneca PLC
  • Biogen, Inc.
  • Biohaven, Ltd.
  • Eisai Co., Ltd.
  • H. Lundbeck A/S
  • Ionis Pharmaceuticals, Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Neurelis, Inc.
  • Neurocrine Biosciences, Inc.
  • Neurona Therapeutics, Inc.
  • Ovid Therapeutics, Inc.
  • Pfizer, Inc.
  • Sanofi SA
  • UCB SA
  • Voyager Therapeutics, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Neurologic Disorders Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Neurologic Disorders Drives Demand for Therapeutics
    • Advancements in Neurotherapeutics Propel Market Growth
    • Growing Awareness of Neurologic Health Expands Addressable Market Opportunity
    • Development of Precision Medicine and Targeted Therapies Strengthens Business Case
    • Innovations in Neurostimulation and Neuromodulation Therapies Generate Market Interest
    • Development of Regenerative Medicine and Stem Cell Therapies Propels Market Growth
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Neurologic Disorders Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Neurologic Disorders Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Neurologic Disorders Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Anticholinergic Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Anticholinergic Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Anticholinergic Drug Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Analgesics Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Analgesics Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Analgesics Drug Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Antiepileptic Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Antiepileptic Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Antiepileptic Drug Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Neurologic Disorders Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Neurologic Disorders Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Neurologic Disorders Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Neurologic Disorders Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Neurologic Disorders Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • JAPAN
    • Neurologic Disorders Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Neurologic Disorders Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for Neurologic Disorders Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • CHINA
    • Neurologic Disorders Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: China 16-Year Perspective for Neurologic Disorders Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 47: China Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: China 16-Year Perspective for Neurologic Disorders Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • EUROPE
    • Neurologic Disorders Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Neurologic Disorders Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Neurologic Disorders Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Neurologic Disorders Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Neurologic Disorders Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • FRANCE
    • Neurologic Disorders Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 59: France Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: France 16-Year Perspective for Neurologic Disorders Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: France 16-Year Perspective for Neurologic Disorders Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • GERMANY
    • Neurologic Disorders Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Neurologic Disorders Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for Neurologic Disorders Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Neurologic Disorders Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for Neurologic Disorders Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Neurologic Disorders Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 77: UK Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Neurologic Disorders Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: UK 16-Year Perspective for Neurologic Disorders Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Spain 16-Year Perspective for Neurologic Disorders Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Spain 16-Year Perspective for Neurologic Disorders Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Russia 16-Year Perspective for Neurologic Disorders Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Russia 16-Year Perspective for Neurologic Disorders Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for Neurologic Disorders Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Rest of Europe 16-Year Perspective for Neurologic Disorders Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Neurologic Disorders Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Neurologic Disorders Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Neurologic Disorders Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Neurologic Disorders Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Neurologic Disorders Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Neurologic Disorders Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Australia 16-Year Perspective for Neurologic Disorders Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: Australia 16-Year Perspective for Neurologic Disorders Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • INDIA
    • Neurologic Disorders Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 116: India Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: India 16-Year Perspective for Neurologic Disorders Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 119: India Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: India 16-Year Perspective for Neurologic Disorders Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: South Korea 16-Year Perspective for Neurologic Disorders Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: South Korea 16-Year Perspective for Neurologic Disorders Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Neurologic Disorders Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Neurologic Disorders Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Neurologic Disorders Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Neurologic Disorders Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Neurologic Disorders Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Neurologic Disorders Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for Neurologic Disorders Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Argentina 16-Year Perspective for Neurologic Disorders Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Argentina 16-Year Perspective for Neurologic Disorders Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Brazil 16-Year Perspective for Neurologic Disorders Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: Brazil 16-Year Perspective for Neurologic Disorders Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: Mexico 16-Year Perspective for Neurologic Disorders Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: Mexico 16-Year Perspective for Neurologic Disorders Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 163: Rest of Latin America 16-Year Perspective for Neurologic Disorders Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 166: Rest of Latin America 16-Year Perspective for Neurologic Disorders Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Neurologic Disorders Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Neurologic Disorders Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Neurologic Disorders Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Neurologic Disorders Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for Neurologic Disorders Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 178: Iran 16-Year Perspective for Neurologic Disorders Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 181: Iran 16-Year Perspective for Neurologic Disorders Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 184: Israel 16-Year Perspective for Neurologic Disorders Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 187: Israel 16-Year Perspective for Neurologic Disorders Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 190: Saudi Arabia 16-Year Perspective for Neurologic Disorders Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 193: Saudi Arabia 16-Year Perspective for Neurologic Disorders Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 196: UAE 16-Year Perspective for Neurologic Disorders Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 199: UAE 16-Year Perspective for Neurologic Disorders Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 202: Rest of Middle East 16-Year Perspective for Neurologic Disorders Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 205: Rest of Middle East 16-Year Perspective for Neurologic Disorders Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • AFRICA
    • Neurologic Disorders Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 208: Africa 16-Year Perspective for Neurologic Disorders Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 211: Africa 16-Year Perspective for Neurologic Disorders Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030

IV. COMPETITION